1 |
Gane, E., Poordad, F., Wang, S., Asatryan, A., Kwo, P.Y., Lalezari, J., Wyles, D.L., Hassanein, T., Aguilar, H., Maliakkal, B., et al. (2016). High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology 151, 651-659.e1.
DOI
|
2 |
Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.H., O'Boyle, D.R., 2nd., et al. (2010). Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96-100.
DOI
|
3 |
Ikeda, H., Watanabe, T., Okuse, C., Matsumoto, N., Ishii, T., Yamada, N., Shigefuku, R., Hattori, N., Matsunaga, K., and Nakano, H. (2016). Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir. Journal of Medical Virology 89, 99-105.
|
4 |
Ishida, H., Tatsumi, T., Hosui, A., Nawa, T., Kodama, T., Shimizu, S., Hikita, H., Hiramatsu, N., Kanto, T., and Hayashi, N. (2011). Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem. Biophys. Res. Commun. 412, 92-97.
DOI
|
5 |
Lawitz, E., Poordad, F.F., Pang, P.S., Hyland, R.H., Ding, X., Mo, H., Symonds, W.T., Mchutchison, J.G., and Membreno, F.E. (2014). Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383, 515-523.
DOI
|
6 |
Li, S., Duan, X., Li, Y., Liu, B., Mcgilvray, I., and Chen, L. (2014). MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J. Viral Hepat. 21, 121-128.
DOI
|
7 |
Lim, E.J., El, K.K., Chin, R., Earnest-Silveira, L., Angus, P.W., Bock, C.T., Nachbur, U., Silke, J., and Torresi, J. (2014). Hepatitis C virusinduced hepatocyte cell death and protection by inhibition of apoptosis. J. Gen. Virol. 95, 2204-2215.
DOI
|
8 |
Lin, C.W., Jones, A.K., Liu, W., and Dutta, S. (2015). Population pharmacokinetics of a pangenetic NS5A inhibitor, ABT-530, in HCV infected patients with and without cirrhosis. J. Pharmacokinet. Pharmacodyn. 42, S86.
|
9 |
Ling, T., Yu, W., Lei, C., Selyutin, O., Dwyer, M.P., Nair, A.G., Mazzola, R., Kim, J.H., Sha, D., Yin, J., et al. (2016). The discovery of ruzasvir (MK-8408): a potent, pan-genotype HCV NS5A inhibitor with optimized activity against common resistance-associated polymorphisms. J. Med. Chem. 60, 290-306.
|
10 |
Liu, Y.P., Lee, J.J., Lai, T.C., Lee, C.H., Hsiao, Y.W., Chen, P.S., Liu, W.T., Hong, C.Y., Lin, S.K., Ping, K.M., e t al. (2015). Suppressive function of low-dose deguelin on the invasion of oral cancer cells by down-regulating TNF- -induced signaling. Head Neck 38, E524-E534.
|
11 |
Majumder, M., Ghosh, A.K., Steele, R., Zhou, X.Y., Phillips, N.J., Ray, R., and Ray, R.B. (2002a). Hepatitis C virus NS5A protein impairs TNFmediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology 294, 94-105.
DOI
|
12 |
Qiu, T., Zhou, L., Wang, T., Xu, J., Wang, J., Chen, W., Zhou, X., Huang, Z., Zhu, W., and Shu, Y. (2013). miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int. J. Mol. Med. 32, 593-598.
DOI
|
13 |
Majumder, M., Ghosh, A.K., Steele, R., Zhou, X.Y., Phillips, N.J., Ray, R., and Ray, R.B. (2002b). Hepatitis C virus NS5A protein impairs TNFmediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology 294, 94-105.
DOI
|
14 |
Mitupatum, T., Aree, K., Kittisenachai, S., Roytrakul, S., Puthong, S., Kangsadalampai, S., and Rojpibulstit, P. (2016). mRNA expression of Bax, Bcl-2, p53, Cathepsin B, Caspase-3 and Caspase-9 in the HepG2 cell line following induction by a novel monoclonal Ab Hep88 mAb: cross-talk for paraptosis and apoptosis. Asian Pac. J. Cancer Prev. 17, 703-712.
DOI
|
15 |
Miyasaka, Y., and Watanabe, M. (2003). Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alphamediated apoptosis in Huh7 cells. J. Infect. Dis. 188, 1537-1544.
DOI
|
16 |
Mogalian, E., Mathias, A., Brainard, D., Shen, G., Mcnally, J., Sajwani, K., Robson, R., Ries, D., Lasseter, K., and Marbury, T. (2015). P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. J. Hepatol. 62, S590-S591.
|
17 |
Organization, W.H. (2015). EN fact sheets: hepatitis C.
|
18 |
Trebicka, J., Anadol, E., Elfimova, N., Strack, I., Roggendorf, M., Viazov, S., Wedemeyer, I., Drebber, U., Rockstroh, J., and Sauerbruch, T. (2013). Hepatic and serum levels of miR-122 after chronic HCVinduced fibrosis. J. Hepatol. 58, 234-239.
DOI
|
19 |
Vermeulen, L., Wilde, G.D., Damme, P.V., Berghe, W.V., and Haegeman, G. (2003). Transcriptional activation of the p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 22, 1313-1324.
DOI
|
20 |
Weil, C., Nwankwo, C., Friedman, M., Kenet, G., Chodick, G., and Shalev, V. (2016). Epidemiology of hepatitis C virus infection in a large israeli health maintenance organization. J. Med. Virol. 56, 1907-1915.
|
21 |
Zeng, J., Chen, S., Li, N., Chen, L., Su, J., Niu, G., Zhu, S., and Liang, Y. (2015). Sasanquasaponin from Camellia oleifera Abel. induces apoptosis via Bcl-2, Bax and caspase-3 activation in HepG2 cells. Mol. Med. Rep. 12, 1997-2002.
DOI
|
22 |
Xiao, Y., Tian, Q., He, J., Huang, M., Yang, C., and Gong, L. (2016). MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor. Oncotargets Ther. 9, 3535-3544.
|
23 |
Yin, Z.L., Wang, Y.L., Ge, S.F., Guo, T.T., Wang, L., Zheng, X.M., and Liu, J. (2015). Reduced expression of miR-503 is associated with poor prognosis in cervical cancer. Eur. Rev. Med. Pharmacol. Sci. 19, 4081- 4085.
|
24 |
Yu, W., Coburn, C.A., Nair, A.G., Wong, M., Rosenblum, S.B., Zhou, G., Dwyer, M.P., Tong, L., Hu, B., Zhong, B., et al. (2016). Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK- 8742. Bioorg. Med. Chem. Lett. 26, 3414-3420.
DOI
|
25 |
Zhao, Q., Yang, S.T., Wang, J.J., Zhou, J., Xing, S.S., Shen, C.C., Wang, X.X., Yue, Y.X., Song, J., Chen, M., et al. (2015). TNF alpha inhibits myogenic differentiation of C2C12 cells through activation and impairment of IGF-1 signaling pathway. Biochem. Biophys. Res. Commun. 458, 790-795.
DOI
|
26 |
Zhou, R., Gong, A.Y., Chen, D., Miller, R.E., Eischeid, A.N., and Chen, X.M. (2013). Histone deacetylases and signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503. PLos One 8, e65153.
DOI
|
27 |
Caporali, A., Meloni, M., Nailor, A., Mitic, T., Shantikumar, S., Riu, F., Sala-Newby, G.B., Rose, L., Besnier, M., Katare, R., et al. (2015). -dependent activation of regulates microRNA-503 transcription and pericyte-endothelial crosstalk in diabetes after limb ischaemia. Nat. Commun. 6, 8024.
DOI
|
28 |
Park, K.J., Choi, S.H., Lee, S.Y., Hwang, S.B., and Lai, M.M. (2002). Nonstructural 5A protein of hepatitis C virus modulates tumor necrosis factor alpha-stimulated nuclear factor kappa B activation. J. Biol. Chem. 277, 13122-13128.
DOI
|
29 |
Bandiera, S., Pernot, S., El Saghir, H., Durand, S.C., Thumann, C., Crouchet, E., Ye, T., Fofana, I., Oudot, M.A., Barths, J., et al. (2016). Hepatitis C virus-induced upregulation of microRNA miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis. J. Virol. 90, 6387-6400.
DOI
|
30 |
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
DOI
|
31 |
Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Jr, B.R., Fried, M.W., Terrault, N.A., O'Leary, J.G., Vargas, H.E., et al. (2015). Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 149, 649-659.
DOI
|
32 |
Chen, X., Hu, H., Guan, X., Xiong, G., Wang, Y., Wang, K., Li, J., Xu, X., Yang, K., and Bai, Y. (2012). CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int. J. Cancer 130, 1607-1613.
DOI
|
33 |
Coburn, C.A., Meinke, P.T., Chang, W., Fandozzi, C.M., Graham, D.J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., et al. (2013). Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 8, 1930-1940.
DOI
|